Metabolic abnormalities and overweight in HIV/AIDS persons-treated with antiretroviral therapy
Palabras clave:
Overweight, Obesity, HIV, Dyslipidemia, Insulin resistanceResumen
Objective
To describe the proportion of overweight among patients with human immunodeficiency virus/Acquired Immune Deficiency Syndrome and correlate overweight and highly active antiretroviral therapy with metabolic complications.
Methods
A cross-sectional study was conducted among human immunodeficiency virus/Acquired Immune Deficiency Syndrome outpatients undergoing nutritional therapy from 2000 to 2006 in a University Health Center. The sample consisted of 393 human immunodeficiency virus/Acquired Immune Deficiency Syndrome patients. Nutritional and medical records were used as a source of data on personal, clinical and biochemical information. Data analysis included descriptive statistics and the Chi-square test.
Results
Sixty-nine percent of the patients were males aging from 26 to 49 years. Overweight and obesity were identified in 49% of this population. The most important metabolic complications were low levels of high-density lipoprotein (70%) and high levels of triglycerides (48%) and cholesterol (40%). Higher body mass index was associated with higher lipid levels and more evidence of insulin resistance.
Conclusion
This study demonstrated an important proportion of overweight and obesity among human immunodeficiency virus/Acquired Immune Deficiency Syndrome patients. These results suggest that nutritional interventions and lifestyle modifications may be useful strategies to decrease the cardiovascular risk in this population.
Descargas
Citas
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Bol Epidemiol Aids e DST. 2006; 3(1)3-4.
Egir E, Vaichulonis CG, Oliveira MD. Adesão à terapêutica anti-retroviral por indivíduos com HIV/AIDS assistidos em uma instituição do interior paulista. Rev Latino-Am Enfermagem. 2005; 13(5):634-41.
Portela MC, Lotrowska M. Assistência aos pacientes com HIV/AIDS no Brasil. Rev Saúde Pública. 2006; 40(Supl 1):70-9.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Recomendações para a terapia anti-retroviral em adultos e adolescentes infectados pelo HIV. 6 ed. Brasília; 2006. Série Normas e Manuais Técnicos.
Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drugs Targests Cardiovasc Haematol Disord. 2005; 5(4):337-43.
Yu PC, Calderaro D, Lima EMO, Caramelli B. Terapia hipolipemiante em situações especiais: síndrome da imunodeficiência adquirida. Arq Bras Cardiol 2005; 85(Suppl 5):58-61.
The data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. New Eng J Med. 2003; 349(21): 1993-2003.
Savès M, Chêne G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37(2):292-8.
Thiébaut R, Savès M, Mercié P, Cipriano C, Chêne G, Dabis F. Épidémiologie du risque vasculaire d´origine athéroscléreuse chez les patients infectés par le VIH-1. Presse Med. 2003, 32(30):1419-26.
Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006; 43(4): 458-66.
Hendricks KM, Willis K, Houser R, Jones CY. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006, 25(4):321-31.
Jaime PC, Florindo AA, Latorre MRDO, Brasil BG, Santos ECM, Segurado AAC. Prevalência de sobrepeso e obesidade abdominal em indivíduos portadores de HIV/AIDS, em uso de terapia anti-retroviral de alta potência. Rev Bras Epidemiol. 2004; 7(1):65-72.
Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nutr. 2005; 25(1):391-406.
Visnegarwala F, Raghavan SS, Mullin CM, Bartsch G, Wang J, Kotler D, et al. Sex differences in the association of HIV disease characteristics and body composition in antiretroviral naïve persons. Am J Clin Nutr. 2005; 82(4):850-6.
Chêne G. Risque cardiovasculaire et VIH. Impact des traitements antirétroviraux. La lettre de l´Infectiologue. 2004; 2(mars-avril):4-5.
Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIVinfected patients. Curr Pharm Des. 2003; 9(18): 1475-8.
El-Sadr WM, Mullin CM, Carr A, Gilbert C, Rapport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral naïve cohort. HIV Med. 2005; 6(2): 114-21.
Delarue J, Allain G, Guillerm S. Le syndrome métabolique. Nutr Clin Met. 2006; 20(2):114-7.
Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population:the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disor. 2005; 5(3):255-62.
Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of a lifestyle modification program in HIV-infected patients with metabolic syndrome. AIDS. 2006; 20(4):1843-50.
Davidson MH. Management of dyslipidemia in patients with complicated metabolic syndrome. A J Cardiol. 2005; 96(4A):22E-5E.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Luísa Helena Maia LEITE, Ana Beatriz de Mattos Marinho SAMPAIO
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
